GlassScriptPhysician profile
Maia Eng
NPI 1043604515
$29,389.08
in general payments reported to CMS, 2019-2025
29 companies · $2,172 in 2025
The $2,172 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,125 · 2020: $1,258 · 2021: $12K · 2022: $6,366 · 2023: $2,843 · 2024: $2,967 · 2025: $2,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,981.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $12,625.22 | 2019-2025 | Mitraclip, Cardiomems |
| Boston Scientific Corporation | $6,616.31 | 2019-2025 | Watchman Flx, Watchman Access System, Synergy |
| Siemens Medical Solutions USA, INC. | $1,534.12 | 2022 | |
| Biotronik INC. | $1,465.89 | 2021-2025 | Acticor 7 Vr-T Dx, Amvia Edge |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,137.90 | 2019-2023 | Lifevest |
| Heartflow, INC. | $801.50 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $591.21 | 2021-2024 | Gore Cardioform Septal Occluder |
| Medtronic, INC. | $476.54 | 2023-2024 | Micra, Corevalve Evolut R |
| Shockwave Medical, INC | $469.17 | 2020-2022 | |
| Inari Medical, INC. | $397.25 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Edwards Lifesciences Corporation | $392.98 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $368.23 | 2019-2025 | Repatha, Repatha |
| Abiomed | $339.95 | 2019-2021 | |
| Chiesi USA, INC. | $325.54 | 2019-2023 | Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $319.74 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $220.32 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.92 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $202.50 | 2019-2024 | Camzyos, Eliquis |
| Teleflex LLC | $170.13 | 2022 | |
| Baxter Healthcare | $155.47 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $142.23 | 2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $139.95 | 2025 | |
| Pfizer INC. | $82.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $55.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $53.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $46.74 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.03 | 2024 | Entyvio |
| Exact Sciences Corporation | $14.05 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $14.04 | 2025 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maia Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.